Tesamorelin has reduced visceral adipose tissue by 15–18% across Phase III randomized controlled trials — here is what the literature has measured.

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), modified at the N-terminus with a trans-3-hexenoic acid group that confers resistance to dipeptidyl peptidase-IV (DPP-IV) degradation. The FDA approved the compound in 2010 under NDA 022505 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.^[1]

Across two pivotal Phase III randomized controlled trials and a 52-week extension study, 2 mg/day subcutaneous tesamorelin produced a 15.2–18% reduction in visceral adipose tissue (VAT) area compared to placebo — a statistically robust and metabolically meaningful outcome that justified the regulatory approval.^[1][2][3] Concurrently, triglycerides decreased by approximately 50 mg/dL and adiponectin increased, while fasting glucose remained metabolically stable in the trial populations.^[4]

Two dedicated secondary trials extended these findings to the liver. A 6-month randomized trial (n=61) found tesamorelin reduced hepatic fat fraction by 2.0 percentage points versus a 0.9 point increase in the placebo group (P=0.003).^[5] A 12-month Phase 2 double-blind trial in HIV-infected patients with non-alcoholic fatty liver disease documented a 37% relative reduction in liver fat fraction, with 35% of tesamorelin recipients versus only 4% of placebo recipients achieving a hepatic fat fraction below 5%.^[6]

Beyond body composition, a controlled trial in adults aged 55–87 years found that 20 weeks of tesamorelin at 1 mg/day improved executive function (P=0.005) and raised IGF-1 by 117% into the physiological young-adult range.^[7]

A 2026 meta-analysis pooling five randomized controlled trials quantified the body-composition benefit at −27.71 cm² VAT, −1.18 kg trunk fat, −4.28% hepatic fat, and +1.42 kg lean body mass, without perturbation of glucose or serious adverse events.^[16]

Tesamorelin — also designated TH9507 — is the full 44-amino-acid sequence of human GHRH(1-44)-NH2 with a single structural modification: a trans-3-hexenoic acid group added to the N-terminus. This modification blocks cleavage by DPP-IV, extending the compound's plasma half-life from approximately 7 minutes (native GHRH) to 26–38 minutes (tesamorelin) while preserving full agonist activity at the GHRH receptor (GHRH-R).^[9]

Tesamorelin is classified as a peptide hormone analogue, not a steroidal compound. It stimulates endogenous, pulsatile GH secretion rather than supplying GH exogenously — a mechanistic distinction with clinical significance: physiological pulsatility is preserved, and the hypothalamic-pituitary-somatostatin feedback axis remains functional.

A population pharmacokinetic analysis confirmed a plasma clearance of approximately 1,060 L/h and a volume of distribution of approximately 200 L; absorption fraction increased 13.1% from day 1 to day 14, consistent with a cumulative receptor-priming effect.^[9] For tesamorelin dosage data from the clinical trials, see the dedicated dosage page.

Tesamorelin binds with high affinity to GHRH receptors (Gs-coupled GPCRs) on somatotroph cells in the anterior pituitary. Receptor activation initiates the adenylyl cyclase/cAMP/PKA cascade, triggering pulsatile GH synthesis and release. Elevated GH then drives hepatic synthesis of insulin-like growth factor-1 (IGF-1) via JAK2/STAT5 signaling.^[1]

The downstream lipolytic effect is selective for visceral adipose depots. IGF-1 activates hormone-sensitive lipase in visceral adipocytes, mobilizing stored triglycerides and reducing VAT area without meaningfully changing subcutaneous fat or BMI — an unusual specificity not seen with exogenous recombinant GH.^[1][3]

For the liver, tesamorelin appears to operate through a distinct secondary pathway. Hepatic transcriptomic analysis in HIV-associated NAFLD patients found significant upregulation of oxidative phosphorylation gene sets and downregulation of inflammatory and fibrosis-related gene sets — a gene-expression profile shift that correlated with improved fibrosis markers.^[12]

For a full treatment of the GHRH receptor mechanism, see GHRH receptor mechanism.

Tesamorelin FDA approval was granted on November 10, 2010, under NDA 022505 (Egrifta, 1 mg/vial formulation), based on two Phase III randomized controlled trials (LIPO-010 and LIPO-011) in HIV-infected adults with lipodystrophy-associated abdominal fat accumulation.^[1][2]

A higher-concentration formulation (Egrifta SV, 2 mg/vial) was approved under the same NDA in 2019, simplifying reconstitution. Theratechnologies holds the marketing authorization. Health Canada and EMA approvals exist for the same HIV-lipodystrophy indication.

Tesamorelin is not approved for use outside the HIV-lipodystrophy indication; all other investigational applications — NAFLD, cognitive function, type 2 diabetes — remain off-label research.

Tesamorelin falls under the WADA Prohibited List (S2 category: peptide hormones, growth factors, and related substances) when used in sporting contexts; GHRH analogues are explicitly listed.

The published research record covers four primary areas: (1) visceral fat reduction in HIV-associated lipodystrophy, the approved indication; (2) hepatic steatosis and NAFLD in HIV-infected patients; (3) cognitive function in aging and mild cognitive impairment; and (4) body composition and metabolic parameters in non-HIV populations including type 2 diabetes.

Across this literature, the safety profile has been consistently described as manageable. The most common adverse events in clinical trials were injection-site reactions, arthralgias, myalgias, and mild fluid retention.^[1][2] Transient glucose elevation was observed in some trials; a 12-week study in type 2 diabetes patients found no significant change in fasting glucose or HbA1c, while total and non-HDL cholesterol decreased significantly in the 2 mg group.^[11]

For a systematic view of tesamorelin side effects as reported in the trial literature, see the dedicated page. For the visceral fat reduction results and other efficacy endpoints, see the research page.